Oncology Nursing News®

Register now to learn about a new option for relapsed or refractory follicular lymphoma

Blood Cancers

FDA Approves Belantamab Mafodotin-blmf to Treat R/R Multiple Myeloma

FDA Approves Belantamab Mafodotin-blmf to Treat R/R Multiple Myeloma

BY GINA COLUMBUS

$FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL$

FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL

BY KRISTI ROSA

Study Aims to Evaluate Duvelisib in Reducing Lung Inflammation in Severe COVID-19 Cases

Study Aims to Evaluate Duvelisib in Reducing Lung Inflammation in Severe COVID-19 Cases

BY HAYLEY VIRGIL

High Body Weight Shows Trend Toward Improved Myeloma Outcomes

High Body Weight Shows Trend Toward Improved Myeloma Outcomes

BY RYAN MCDONALD

Genetic Testing Improves Treatments, Outcomes in MPNs and MDS

Genetic Testing Improves Treatments, Outcomes in MPNs and MDS

BY HAYLEY VIRGIL

$FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma$

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma

BY GINA COLUMBUS

$FDA Sets Review Date for Steroid-Refractory Pediatric Acute GVHD Treatment$

FDA Sets Review Date for Steroid-Refractory Pediatric Acute GVHD Treatment

BY KRISTI ROSA

FDA Approval Sought for Selinexor in Pretreated Myeloma

FDA Approval Sought for Selinexor in Pretreated Myeloma

BY KRISTI ROSA

$FDA Panel OKs Belantamab Mafodotin for Relapsed/Refractory Myeloma$

FDA Panel OKs Belantamab Mafodotin for Relapsed/Refractory Myeloma

BY GINA COLUMBUS

$Second-Line Pembrolizumab for Relapsed/Refractory Hodgkin Lymphoma$

Second-Line Pembrolizumab for Relapsed/Refractory Hodgkin Lymphoma

BY KRISTI ROSA

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.